Evidence map›Paper›PMID 40668100›Full record

ArticleThe Journal of infectious diseases2025

The Burden of HMPV- and Influenza-Associated Hospitalizations in Adults in New Zealand Before and After the COVID-19 Pandemic, 2012-2023.

Nayyereh Aminisani, Briony Fanslow, Timothy Wood, Lauren Jelley, Louise Thorn, Ruth Seeds, Conroy Wong, Adrian Trenholme, Cameron C Grant, Q Sue Huang

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nayyereh AminisaniInstitute of Environmental Science and Research, Wellington, New Zealand.
Briony FanslowInstitute of Environmental Science and Research, Wellington, New Zealand.
Timothy WoodInstitute of Environmental Science and Research, Wellington, New Zealand.
Lauren JelleyInstitute of Environmental Science and Research, Wellington, New Zealand.ORCID 0000-0001-5993-6266
Louise ThornInstitute of Environmental Science and Research, Wellington, New Zealand.
Ruth SeedsInstitute of Environmental Science and Research, Wellington, New Zealand.
Conroy WongUniversity of Auckland, Auckland, New Zealand.
Adrian TrenholmeDepartment of Paediatrics: Child & Youth Health, University of Auckland, Auckland, New Zealand.
Cameron C GrantDepartment of Paediatrics: Child & Youth Health, University of Auckland, Auckland, New Zealand.
Q Sue HuangInstitute of Environmental Science and Research, Wellington, New Zealand.ORCID 0000-0002-3923-5195

Funding

AstraZenecaCDC HHS U01IP000480IcosavaxMinistry of HealthNCIRD CDC HHS U01 IP000480
6 · The paper itself

Abstract

backgroundUnderstanding temporal trends of influenza and human metapneumovirus (HMPV) infections among adults and their return after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) pandemic is important for designing prevention and control strategies.

methodsUsing the New Zealand hospital-based surveillance dataset, we compared the population-based incidence, seasonality, and clinical characteristics of influenza and HMPV infections among hospitalized adults aged 20 years and older with acute respiratory infections (ARI) in Auckland, New Zealand, from 2012 to 2023.

resultsIn the surveillance project, 37 185 ARI hospitalizations were detected from 2012 to 2023 among adults 20 years and older. Of the 21 649 illnesses tested for HMPV, 735 (3.4%) were positives and of the 24 138 tested for influenza, 3623 (15.0%) were positives. Crude rates of annual ARI hospitalizations per 100 000 adult residents were 9.7 (95% confidence interval [CI], 9-10.4) for HMPV and 48.2 (95% CI, 46.6-49.7) for influenza. The highest hospitalization rates for both viruses were in those aged 80 years or older, those of Māori or Pacific ethnicity, and those living in low socioeconomic status areas. There were no statistically significant differences in the HMPV-associated ARI hospitalization rates before and after the COVID-19 pandemic. In contrast, influenza-associated hospitalization rates per 100 000 were 43.0 before the pandemic, increased to 54.4 in 2022, and then 79.5 in 2023, with significant increases across most demographic groups.

conclusionsAlthough HMPV infections accounted for fewer ARI hospitalizations than influenza infections in all study years, relative to younger adults, HMPV-associated ARI hospitalization rates were significantly higher in older adults due to the high prevalence of underlying chronic conditions in this age group. This highlights a need for vaccine/antiviral intervention.

Indexed as

COVID-19HospitalizationInfluenza, HumanParamyxoviridae InfectionsAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMetapneumovirusMiddle AgedNew ZealandPandemicsSARS-CoV-2acute respiratory infectionadultsburden of diseasehuman metapneumovirusincidenceinfluenza

Identifiers

PMID40668100
PMCPMC12265057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.